BTK and B-cell chronic lymphocytic leukemia: Ibrutinib targets BTK expressed by CLL-associated macrophages (also known as nurse-like cells, NLC) accentuating their immunosuppressive profile through up-regulation of M2 polarization markers and impairing the phagocytic activity (11).